Budget Impact Analysis of Mepolizumab for Eligible Patients in the Setting of a Severe Asthma Clinic Within Dubai Health Authority (DHA)
Bassam Mahboub,1 Ahmed Mohy,2 Islam El-Amir,2 Tamara Lukić,3 Raef Gouhar,4 Saeed Noibi5 1Pulmonary Medicine Department, Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates; 2Medical Affairs Department, GSK, Jeddah, Kingdom of Saudi Arabia; 3GSK Research and Development, D...
Saved in:
Main Authors: | Mahboub B (Author), Mohy A (Author), El-Amir I (Author), Lukić T (Author), Gouhar R (Author), Noibi S (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Asthma control factors in the Gulf Cooperation Council (GCC) countries and the effectiveness of ICS/LABA fixed dose combinations: a dual rapid literature review
by: Saeed Noibi, et al.
Published: (2020) -
Severe Pediatric Asthma Therapy: Mepolizumab
by: Nicola Ullmann, et al.
Published: (2022) -
Clinical usefulness of mepolizumab in severe eosinophilic asthma
by: Menzella F, et al.
Published: (2016) -
Use of Mepolizumab in Children and Adolescents with Asthma in the USA
by: Jaclyn Davis, et al.
Published: (2022) -
Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation
by: Hamouda M, et al.
Published: (2023)